Notably, this data indicates the possibility that E12 is applicable in treating not only CRC, but also in a wider range of clinical contexts such as other S100A4-prognostic cancers that display aberrant Wnt-signaling pathways, such as breast, ovarian, lung, gastric and melanoma cancer 55-59. The gene discussed is S100A4; the disease is cancer.